BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...
Two Pappas Ventures' Portfolio companies make FierceMedicalDevices' 2012 Fierce 15 list: CardioDx and TyRx
News | 10. 02. 2012
FierceMedicalDevices named two Pappas Ventures' portfolio companies to the 2012 Fierce 15 list, the inaugural list of the most innovative and exciting medical device companies. CardioDx is a cardiovascular molecular diagnostics company based in Palo Alto and TyRx is a New Jersey device company developing a range of drug-eluting implantable devices.
- "CardioDx scored a major victory in August, securing Medicare reimbursement for Corus CAD, and the company is optimistic that private insurers will follow suit, opening up an even larger market for the diagnostic."
- "Four years after gaining initial FDA clearance and three years after hitting the market, Tyrx has already sold more than 30,000 units. And the company is waiting for FDA clearance of a fully bioresorbable version of Aigis that dissolves within 90 days (version one is partially dissolvable)."
